Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Renal Care|August 15, 2013
Laboratory database population surveillance to improve detection of progressive chronic kidney diseaseDavid M Kennedy, Kamaljit Chatha, Hugh C Rayner
Vascular Pharmacology|July 18, 2018
Chemerin in human cardiovascular diseaseJaspreet Kaur, Harman S Mattu, Kamaljit Chatha, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 13, 2008
Methylation of the imprinted GNAS1 gene in cell-free plasma DNA: equal steady-state quantities of methylated and unmethylated DNA in plasmaWilliam M Puszyk, Kamaljit Chatha, Selina Elsenheimer, et al.
BMC Medicine|July 16, 2020
Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemicIoannis Kyrou, Emmanouil Karteris, Tim Robbins, et al.
International Journal of Molecular Sciences|May 28, 2022
Cardiovascular Biomarkers: Lessons of the Past and Prospects for the FutureFarah Omran, Ioannis Kyrou, Faizel Osman, et al.
International Journal of Oncology|May 30, 2020
Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19Periklis Katopodis, Vladimir Anikin, Harpal S Randeva, et al.
Molecular Medicine Reports|October 1, 2020
Neuropilin‑1 as a new potential SARS‑CoV‑2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID‑19Julie Davies, Harpal S Randeva, Kamaljit Chatha, et al.
International Journal of Molecular Medicine|July 25, 2020
Co‑expression of peripheral olfactory receptors with SARS‑CoV‑2 infection mediators: Potential implications beyond loss of smell as a COVID‑19 symptomRachel Kerslake, Marcia Hall, Harpal S Randeva, et al.
Journal of Clinical Medicine|October 17, 2020
Is There a Link between Bisphenol A (BPA), a Key Endocrine Disruptor, and the Risk for SARS-CoV-2 Infection and Severe COVID-19?Aeman Zahra, Cristina Sisu, Elisabete Silva, et al.
Endocrinology, Diabetes & Metabolism|October 21, 2022
The DAPA-DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity-A longitudinal cohort studyPetra Hanson, Harpal Randeva, Dan J Cuthbertson, et al.
Pageof 2